Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Isovaleric acidemia (IVA) is an autosomal recessively inherited organic aciduria characterized by a deficiency in isovaleryl-CoA dehydrogenase, that has wide clinical variability and that can present in infancy with acute manifestations of vomiting, failure to thrive, seizures, lethargy, a characteristic ''sweaty feet'' odor, acute pancreatitis and mild to severe developmental delay or in childhood with metabolic acidosis (brought on by prolonged fasting, an increased intake of protein-rich food or infections) and that can be fatal if not treated immediately. Chronic intermittent presentations and asymptomatic patients have also been reported.
Features include always present findings: Elevated urinary isovalerylglycine level and Sweaty foot-like odor; and common findings: Intellectual disability, Low muscle tone (hypotonia), Failure to thrive, and Hyperammonemia and others. 41 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 5 | Seizure, Global developmental delay, Intellectual disability |
Blood and immune system | 3 | Low white blood cell count (decreased total leukocyte count), Low platelet count (thrombocytopenia), Low blood cell counts (all types) (pancytopenia) |
Digestive system | 3 | Vomiting, Feeding difficulties in infancy, Acute pancreatitis |
Lab test results | 3 | Increased circulating isovaleric acid concentration, Elevated serum anion gap, Elevated circulating isovalerylcarnitine concentration |
Kidneys and urinary system | 2 | Elevated urinary isovalerylglycine level, Renal Fanconi syndrome |
Growth and development | 2 | Failure to thrive, Weight loss |
Bones and joints | 1 | Bone marrow hypocellularity |
Arms and legs | 1 | Sweaty foot-like odor |
Metabolism | 1 | Metabolic acidosis |
Muscles | 1 | Low muscle tone (hypotonia) |
Heart and blood vessels | 1 | Arrhythmia |
The clinical spectrum of classic isovaleric acidemia (IVA) is broad and differs according to age of onset and severity of disease. Classic IVA is characterized by early onset of acute metabolic decompensations (vomiting, poor feeding, lethargy, hypotonia, seizures, and a distinct odor of sweaty feet), epilepsy, developmental delay, intellectual disability and/or impaired cognition, and movement disorder. Individuals with classic IVA (not identified on newborn screening) may have delayed diagnosis if acute metabolic decompensations occur later in childhood and/or they have nonspecific poor weight gain, growth deficiency, and developmental delay. Table 3. Select Features of Classic Isovaleric Acidemia Feature | % of Persons w/Feature Identified by NBS1 | Not identified by NBS Early onset w/prompt diagnosis | Delayed diagnosis (missed diagnosis or later onset)
Acute metabolic decompensations | 70%2 | 90%-100%3 | 80%4 |
|---|---|---|---|
Seizures |
IVD encodes isovaleryl-CoA dehydrogenase (426 aa). A mitochondrial matrix enzyme that catalyzes the third step in leucine catabolism, where isovaleryl-CoA (3-methylbutanoyl-CoA) is metabolized to 3-methylbut-2-enoyl-CoA. Highest expression in Thyroid (164.8 TPM) and Pituitary (77.9 TPM).
Isovaleric acidemia is caused by mutations in the IVD gene on chromosome 15.
The IVD protein participates in mutant IVD tetramer pathway.
IVD is classified as a druggable target (Enzyme category) with score 0.0.
Suggestive Findings
NBS for classic isovaleric acidemia (IVA) is based on the quantification of the first-tier analyte isovalerylcarnitine (as C5-carnitine) in dried blood spots. C5-carnitine (C5) values above the cutoff reported by the screening laboratory are considered positive and suggest a diagnosis of classic IVA; additional testing of urinary organic acids is required to . An algorithm has been proposed for elevated C5 NBS result . Additional testing to decrease false positives includes C5 isobar analysis (when available), which can distinguish isovalerylcarnitine from other isobaric carnitines (pivaloylcarnitine, 2-methylbutyrylcarnitine, and N-valerylcarnitine) that cannot be distinguished by tandem mass spectrometry .
Source: GeneReviews — "Classic Isovaleric Acidemia"
Scenario 1: Abnormal Newborn Screening (NBS) Result
Table 4a.
Genes of Interest in the Differential Diagnosis of an Infant with NBS Results and/or Other Laboratory Findings Suggestive of Classic Isovaleric Acidemia
Gene(s) | Disorder | MOI | Laboratory Findings | Clinical Findings
| Short/branched-chain acyl-CoA dehydrogenase deficiency (2-methylbutyrylglycinuria) (OMIM 610006) | AR | C51 | • DD
Seizures
Autism
Majority of persons remain asymptomatic
ETFA
ETFB
| Multiple acyl-CoA dehydrogenase deficiency (MADD, glutaric aciduria II) | AR | • C5
Metabolic acidosis
Hypoglycemia1
| • Muscular hypotonia weakness
Liver dysfunction
Cardiomyopathy
Genetic testing for IVD is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for isovaleric acidemia has been reported in the published literature.
No approved treatments are currently available for isovaleric acidemia. The disease remains an area of unmet medical need.
When classic isovaleric acidemia (IVA) is suspected during the diagnostic evaluation, that is, because of increased C5-carnitine concentrations in dried blood spots (acylcarnitine profile) or isovalerylglycine in urine (urine organic acids), metabolic treatment should be initiated immediately. Development and evaluation of treatment plans, training and education of affected individuals and their families, and avoidance of side effects of dietary treatment (i.e., malnutrition, growth failure) require a multidisciplinary approach including multiple subspecialists, with oversight and expertise from a specialized metabolic center.
To establish the extent of disease and needs in an individual diagnosed with classic IVA, the evaluations summarized (if not performed as part of the evaluation that led to the diagnosis) are recommended.
Table 5.
Classic Isovaleric Acidemia: Recommended Evaluations Following Initial Diagnosis
Evaluation | Comment
Consultation w/metabolic physician/ biochemical geneticist specialist metabolic dietitian1 | • Transfer to specialist center w/experience in mgmt of inherited metabolic diseases (strongly recommended)
Consideration of short hospitalization at center of expertise for inherited metabolic conditions to provide caregivers w/detailed education (natural history, maintenance emergency treatment, prognosis, risks for acute encephalopathic crises)
Nutrition/
| In symptomatic children w/feeding problems, ...
Source: GeneReviews — "Classic Isovaleric Acidemia"
1 trial found
In addition to regular evaluations by a metabolic specialist and metabolic dietician, the evaluations summarized in are recommended to monitor existing manifestations, the individual's response to supportive care, and the emergence of new manifestations. Table 7. Classic Isovaleric Acidemia: Recommended Surveillance
Manifestation | Evaluation | Frequency/Comment |
|---|---|---|
Growth | Quantitative analysis of plasma amino acids (ideally sent after a 3-hour protein fast) | At least every 3 months until age 1 year; Every 6 months from ages 1-6 years Laboratory testing (blood gases, albumin, calcium, phosphate, parathyroid hormone, complete blood count, vitamin B12) |
Development | Monitor developmental milestones. | At each visit; Neuropsychological testing using age-appropriate standardized assessments; Standardized quality-of-life assessment tools for affected persons parents/caregivers |
Movement disorder | Assessment for clinical manifestations of movement disorders, severity, response to treatment (physical therapy pharmacologic interventions) | At each visit |
Source: GeneReviews — "Classic Isovaleric Acidemia"
Phenotype severity distribution: 2 always present features, 10 common features.
Estimated prevalence: 1-9 in 100,000 (Uncommon).
1 clinical trial registered. Interventions under study include other interventions. Research is primarily sponsored by academic and government institutions.
19 publications have been identified in PubMed for isovaleric acidemia. Research spans Case Report / Case Series (32%), Basic Science / Preclinical (21%), and Diagnostic / Biomarker (16%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 6 | 32% |
Laboratory research | 4 | 21% |
Testing and diagnosis research | 3 | 16% |
Research summaries | 3 | 16% |
Disease patterns and progression | 2 | 11% |
Other research | 1 | 5% |
Kiss S (2026). [PMID: 42164418](https://pubmed.ncbi.nlm.nih.gov/42164418/). *JIMD Rep*. [Diagnostic / Biomarker]
Deng Z (2026). [PMID: 41938635](https://pubmed.ncbi.nlm.nih.gov/41938635/). *Clin Case Rep*. [Basic Science / Preclinical]
Bandura A (2026). [PMID: 41722717](https://pubmed.ncbi.nlm.nih.gov/41722717/). *Clin Biochem*. [Epidemiology / Natural History]
Zhao HY (2026). [PMID: 42130361](https://pubmed.ncbi.nlm.nih.gov/42130361/). *Zhongguo Dang Dai Er Ke Za Zhi*. [Case Report / Case Series]
Lin Y (2025). [PMID: 40835664](https://pubmed.ncbi.nlm.nih.gov/40835664/). *Sci Rep*. [Epidemiology / Natural History]
Göksoy E (2025). [PMID: 40459186](https://pubmed.ncbi.nlm.nih.gov/40459186/). *J Pediatr Endocrinol Metab*. [Basic Science / Preclinical]
Thimm E (2025). [PMID: 41133704](https://pubmed.ncbi.nlm.nih.gov/41133704/). *Int J Neonatal Screen*. [Review / Meta-Analysis]
Rock R (2025). [PMID: 39318119](https://pubmed.ncbi.nlm.nih.gov/39318119/). *J Inherit Metab Dis*. [Diagnostic / Biomarker]
Huang S (2025). [PMID: 41440809](https://pubmed.ncbi.nlm.nih.gov/41440809/). *Int J Neonatal Screen*. [Review / Meta-Analysis]
Di Costanzo M (2025). [PMID: 40491588](https://pubmed.ncbi.nlm.nih.gov/40491588/). *Front Nutr*. [Other]
Data assembled from 9 of 12 sources · Last updated Oct 4, 2026, 6:15 AM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Prevalent5 |
Prevalent5 |
Speech/language delay | 15%-20%1,6 | 25%4 | Prevalent5 |
Gross/fine motor delay | 5%-16%1,6 | Prevalent4,5 | Prevalent5 |
Intellectual disability/impaired cognition | 10%1 | 15%-18%4 | 55%-56%4 |
Muscular hypotonia | 5%1 | Prevalent4,5 | Prevalent5 |
Movement disorder | 15%1 | Prevalent4,5 | Prevalent5 |
Infantile mortality | 0%1 | 33%4 | 3%4,7 NBS = newborn screening 1. 2. In those with classic IVA identified on newborn screening, 50% of decompensations occur in the neonatal period . 3. In those with classic IVA not identified on newborn screening, most present with metabolic decompensation . 4. 5. 6. |
Source: GeneReviews — "Classic Isovaleric Acidemia"
1.
Source: GeneReviews — "Classic Isovaleric Acidemia"